

# Europe Constrained Peptide Drugs Market: Analysis and Forecast, 2024-2040

<https://marketpublishers.com/r/EC3D5045CB23EN.html>

Date: January 2024

Pages: 0

Price: US\$ 3,950.00 (Single User License)

ID: EC3D5045CB23EN

## Abstracts

This report will be delivered in 1-5 working days.

Introduction to Europe constrained peptide drugs market

The market size is anticipated to be \$0.06 billion in 2026 and is expected to reach \$7.72 billion by 2040, growing at a CAGR of 41.55% during the forecast period 2026-2040. The constrained peptide drugs market is expected to experience significant growth, driven by innovative constrained peptide pipelines that now target more than just receptors. Advances in chemical technologies, the success of synthetic peptides in therapeutics, and their affordability across various diseases are also contributing to the projected growth in the forecast period.

Market Introduction

The Europe constrained peptide drugs market is poised for substantial growth in the coming years. One of the key drivers of this expansion is the region's robust pharmaceutical industry, characterized by a focus on research and development, innovation, and a strong regulatory framework. European pharmaceutical companies have been at the forefront of developing constrained peptide drugs, leveraging cutting-edge technologies and expertise in peptide chemistry.

Additionally, Europe has witnessed a growing demand for novel therapeutic approaches, particularly in the treatment of various diseases such as cancer, autoimmune disorders, and metabolic conditions. Constrained peptides offer a promising solution due to their specificity and potential for enhanced efficacy and safety profiles.

Furthermore, collaborative efforts between academia, research institutions, and pharmaceutical companies in Europe have accelerated the discovery and development of constrained peptide-based therapeutics. This collaborative ecosystem fosters innovation and positions Europe as a significant player in the constrained peptide drugs market.

## Market Segmentation

### Segmentation 1: by Country

Germany

U.K.

France

Italy

Spain

### Segmentation 2: by Company

Bicycle Therapeutics plc

Spexis AG

Santhera Pharmaceuticals

Union Chimique Belge S.A. (UCB)

Biosynth (Pepscan)

Zealand Pharma

How can this report add value to an organization?

**Workflow/Innovation Strategy:** Over the past decade, peptide drug discovery and development has witnessed a renaissance and scientific thrust as the industry has come to acknowledge the capability of peptide therapeutics in addressing unmet medical needs and the potential of this class of molecules to become a significant accompaniment or even favored alternative treatment to biologics and small molecules.

Peptide therapeutics have demonstrated a novel and selective yet safe mode of action for a wide range of indications. The existing and future development of constrained peptide drugs will continue to burgeon upon the strengths of constrained peptides and innovative technologies employed in the discovery and development, including peptide drug conjugates, multifunctional peptides, and cell-penetrating peptides. Furthermore, limitations associated with presently available peptides have resulted in an urgent need for new design, administration, and synthesis in peptide therapeutics, thereby leading to advancements in the development of constrained peptides.

**Growth/Marketing Strategy:** Constrained peptides provide noteworthy advantages over linear peptides. An increase in interest in constrained peptides due to their properties led to advancements in peptide synthesis technologies.

**Competitive Strategy:** Key players in the Europe constrained peptide drugs market have been analyzed and profiled in the study, including manufacturers involved in new product development, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the Europe constrained peptide drugs market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

## Contents

Executive Summary

### **1 DEFINITION**

1.1 Inclusion and Exclusion Criteria

### **2 RESEARCH SCOPE**

2.1 Key Questions Answered in the Report

### **3 RESEARCH METHODOLOGY**

3.1 Constrained Peptides: Research Methodology

3.2 Primary Data Sources

3.3 Secondary Data Sources

3.4 Market Estimation Model

3.5 Criteria for Company Profiling

### **4 MARKETS OVERVIEW**

4.1 Introduction

4.1.1 Structure and Design of Constrained Peptides

4.1.2 Types of Constrained Peptides

4.2 Evolution of Constrained Peptides

4.3 Development of Constrained Peptides as Drugs

4.4 Potential Therapy Areas

4.5 Value Chain-Key Stakeholders

4.6 Key Industry Trends (by Region)

4.7 Key Industry Trends by Route of Administration

4.8 Key Industry Trends-Technological Advancements

4.9 Current Market Size and Growth Potential, \$Billion, 2024-2040

4.1 COVID-19 Impact on Constrained Peptides Drugs Market

4.10.1 Impact on Constrained Peptide Drugs Companies

4.10.2 Clinical Trial Disruptions and Resumptions

### **5 EUROPE**

## 5.1 Constrained Peptide Drugs Market (by Country), \$Billion, 2024-2031

### 5.1.1 Europe

#### 5.1.1.1 U.K.

#### 5.1.1.2 Germany

#### 5.1.1.3 France

#### 5.1.1.4 Italy

#### 5.1.1.5 Spain

## 6 COMPANY PROFILES

### 6.1 Overview

#### 6.2 Bicycle Therapeutics plc

##### 6.2.1 Company Overview

##### 6.2.2 Role of Bicycle Therapeutics plc in the Constrained Peptide Drugs Market

##### 6.2.1 Current Status and Policies for Investigational Drugs

##### 6.2.2 Key Competitors of the Company

##### 6.2.3 Financials

##### 6.2.4 Key Insights about the Financial Health of the Company

##### 6.2.5 Corporate Strategies

###### 6.2.5.1 Synergistic Activities

###### 6.2.5.2 Funding

##### 6.2.6 Business Strategies

###### 6.2.6.1 Clinical Developments

###### 6.2.6.2 Regulatory and Legal

##### 6.2.7 Analyst Perspective

#### 6.3 Spexis AG

##### 6.3.1 Company Overview

##### 6.3.2 Role of Spexis AG in the Constrained Peptide Drugs Market

##### 6.3.3 Current Status and Policies for Investigational Drugs

##### 6.3.4 Key Competitors of the Company

##### 6.3.5 Financials

##### 6.3.6 Key Insights about the Financial Health of the Company

##### 6.3.7 Corporate Strategies

###### 6.3.7.1 Funding

###### 6.3.7.2 Mergers and Acquisitions

###### 6.3.7.3 Synergistic activities

##### 6.3.8 Business Strategies

###### 6.3.8.1 Regulatory and Legal

##### 6.3.9 Analyst Perspective

## 6.4 Santhera Pharmaceuticals

### 6.4.1 Company Overview

### 6.4.2 Role of Santhera Pharmaceuticals in the Constrained Peptide Drugs Market

### 6.4.3 Current Status and Policies for Investigational Drugs

### 6.4.4 Key Competitors of the Company

### 6.4.5 Financials

### 6.4.6 Corporate Strategies

#### 6.4.6.1 Funding

### 6.4.7 Business Strategies

#### 6.4.7.1 Clinical Developments

### 6.4.8 Analyst Perspective

## 6.5 Union Chimique Belge S.A. (UCB)

### 6.5.1 Company Overview

### 6.5.2 Role of Union Chimique Belge S.A. (UCB) in the Constrained Peptide Drugs Market

### 6.5.3 Current Status and Policies for Investigational Drugs

### 6.5.4 Key Competitors of the Company

### 6.5.5 Financials

### 6.5.6 Key Insights about the Financial Health of the Company

### 6.5.7 Corporate Strategies

#### 6.5.7.1 Mergers and Acquisitions

### 6.5.8 Business Strategies

#### 6.5.8.1 Clinical Developments

#### 6.5.8.2 Regulatory and legal

### 6.5.9 Analyst Perspective

## 6.6 Biosynth (Pepscan)

### 6.6.1 Company Overview

### 6.6.2 Role of Biosynth (Pepscan) in the Constrained Peptide Drugs Market

### 6.6.3 Key Competitors of the Company

### 6.6.4 Corporate Strategies

#### 6.6.4.1 License

### 6.6.5 Business Strategies

#### 6.6.5.1 Product Launch

### 6.6.6 Analyst Perspective

### 6.6.7 Zealand Pharma

#### 6.6.7.1 ZP10000 (Preclinical)

##### 6.6.7.1.1 Product Profile

## List Of Figures

### LIST OF FIGURES

- Figure 1: Europe Total Number of Drugs Approved by the U.S. FDA, 2016-2021
- Figure 2: Europe Constrained Peptide Drugs Market, \$Billion, 2024-2031
- Figure 3: Europe Constrained Peptide Drugs Market, \$Billion, 2032-2040
- Figure 4: Europe Constrained Peptide Drugs: Impact Analysis
- Figure 5: Constrained Peptide Drugs Market (by Region), \$Billion, 2024-2040
- Figure 6: Constrained Peptide Drugs Methodology
- Figure 7: Primary Research Methodology
- Figure 8: Epidemiology-Based Approach
- Figure 9: Inducing Conformational Effects
- Figure 10: Two Main Types of Constraints
- Figure 11: Methodology for Restricting Conformation in Peptides
- Figure 12: Types of Constrained Peptides
- Figure 13: Key Milestones in the Evolution of Constrained Peptides
- Figure 14: Major Factors Affecting Constrained Peptide Development
- Figure 15: Value Chain Analysis- Key Stakeholders
- Figure 16: Constrained Peptide Drugs Market (by Region), \$Billion, 2024-2031
- Figure 17: Constrained Peptide Drugs Market (by Region), \$Billion, 2032-2040
- Figure 18: Europe Constrained Peptide Drugs Market, \$Billion, 2024-2031
- Figure 19: Europe Constrained Peptide Drugs Market, \$Billion, 2032-2040
- Figure 20: Constrained Peptide Drugs Market (by Region)
- Figure 21: Constrained Peptide Drugs Market (by Region), \$Billion, 2024-2040
- Figure 22: Europe Constrained Peptide Drugs Market, \$Billion, 2024-2031
- Figure 23: Europe Constrained Peptide Drugs Market, \$Billion, 2032-2040
- Figure 24: Europe: Market Dynamics
- Figure 25: Europe Constrained Peptide Drugs Market (by Country), \$Billion, 2025 and 2040
- Figure 26: U.K. Constrained Peptide Drugs Market, \$Billion, 2024-2031
- Figure 27: U.K. Constrained Peptide Drugs Market, \$Billion, 2032-2040
- Figure 28: Germany Constrained Peptide Drugs Market, \$Billion, 2024-2031
- Figure 29: Germany Constrained Peptide Drugs Market, \$Billion, 2032-2040
- Figure 30: France Constrained Peptide Drugs Market, \$Billion, 2024-2031
- Figure 31: France Constrained Peptide Drugs Market, \$Billion, 2032-2040
- Figure 32: Italy Constrained Peptide Drugs Market, \$Billion, 2024-2031
- Figure 33: Italy Constrained Peptide Drugs Market, \$Billion, 2032-2040
- Figure 34: Spain Constrained Peptide Drugs Market, \$Billion, 2024-2031

Figure 35: Spain Constrained Peptide Drugs Market, \$Billion, 2032-2040

Figure 36: Total Number of Companies Profiled

Figure 37: Bicycle Therapeutics plc: Product Portfolio

Figure 38: Bicycle Therapeutics plc: Overall Financials, \$Million, 2019-2021

Figure 39: Bicycle Therapeutics plc: Revenue (by Region), \$Million, 2019-2021

Figure 40: Bicycle Therapeutics plc: R&D Expenditure, \$Million, 2019-2021

Figure 41: Spexis AG: Product Portfolio

Figure 42: Spexis AG: Overall Financials, \$Million, 2019-2021

Figure 43: Spexis AG: R&D Expenditure, \$Million, 2019-2021

Figure 44: Santhera Pharmaceuticals: Product Portfolio

Figure 45: Santhera Pharmaceuticals: Overall Financials, \$Million, 2019-2021

Figure 46: Union Chimique Belge S.A. (UCB): Product Portfolio

Figure 47: Union Chimique Belge S.A. (UCB): Overall Financials, \$Million, 2019-2021

Figure 48: Union Chimique Belge S.A. (UCB): R&D Expenditure, \$Million, 2019-2021

Figure 49: Biosynth (Pepscan): Product Portfolio



## List Of Tables

### LIST OF TABLES

Table 1: Potential Indications of Constrained Peptide Drugs

Table 2: Potential Therapy Areas of Constrained Peptide Drugs

Table 3: Route of Administration of Constrained Peptide Drugs

Table 4: Impact of COVID-19 on Constrained Peptide Drug Companies

## I would like to order

Product name: Europe Constrained Peptide Drugs Market: Analysis and Forecast, 2024-2040

Product link: <https://marketpublishers.com/r/EC3D5045CB23EN.html>

Price: US\$ 3,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EC3D5045CB23EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970